Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16520138 | 0.93 | KMT2A (0.50) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL25284834 | 0.91 | KMT2A (0.47) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL26906342 | 0.86 | MEN1 (0.46) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL26988028 | 0.86 | APP (0.41) | KMT2A | |
| SCHEMBL19205339 | 0.86 | APP (0.41) | KMT2A | |
| SCHEMBL4980907 | 0.85 | MEN1 (0.48) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL27228991 | 0.85 | MEN1 (0.45) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL27228997 | 0.84 | MEN1 (0.45) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL24424679 | 0.84 | KMT2A (0.45) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL23531641 | 0.84 | KMT2A (0.50) | MEN1KMT2AGPR119MMP13P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | MEN1 1794/4885KMT2A 2336/4885RORC 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.